RxDoctor Payments Data

Cameron Luo, MD

Neurology · New Albany, INNPI 1902809478

Payments from drug & device makers

$7,333in general payments, 2019–2025

Across 532 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759
  • Pfizer$712
  • UCB, Inc.$596
  • Teva Pharmaceuticals USA, Inc.$408
  • Vanda Pharmaceuticals Inc.$344
  • Livanova USA, Inc.$298
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$7,06596%
  • Education$2684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)68$759
Pfizer99$712
UCB, Inc.61$596
Teva Pharmaceuticals USA, Inc.12$408
Vanda Pharmaceuticals Inc.12$344
Livanova USA, Inc.8$298
Amneal Pharmaceuticals LLC16$271
Neurocrine Biosciences, Inc.21$267
Novartis17$265
Biogen14$242
AstraZeneca13$217
Supernus Pharmaceuticals, Inc.13$202
Amgen15$193
Lilly USA, LLC9$171
Argenx US, Inc.8$147
Lundbeck LLC8$124
Biohaven Pharmaceutical Holding Company Ltd.20$123
SK Life Science, Inc.7$120
Eisai Inc.7$116
Catalyst Pharmaceuticals, Inc.6$111
Acadia Pharmaceuticals Inc6$101
Grifols USA, LLC5$96
Sanofi6$86
Neurelis, Inc.5$85
CSL Behring5$76
Upsher-smith Laboratories LLC3$76
Johnson & Johnson(2 entities)4$72
Sumitomo Pharma America, Inc.5$71
Genentech USA, Inc.3$67
Aprecia Pharmaceuticals, LLC4$63
Otsuka America Pharmaceutical, Inc.3$57
Arbor Pharmaceuticals, Inc.4$57
Azurity Pharmaceuticals, Inc.3$53
Boston Scientific2$50
Jazz Pharmaceuticals Inc.2$49
Sunovion Pharmaceuticals Inc.4$49
MDD US Operations, LLC3$48
Xeris Pharmaceuticals, Inc.2$46
EMD Serono, Inc.3$45
Avanir Pharmaceuticals, Inc.3$39
GE HealthCare2$37
Scilex Pharmaceuticals Inc.2$31
Kyowa Kirin, Inc.2$31
Biohaven Pharmaceuticals, Inc.2$30
Metacel Pharmaceuticals LLC1$28
Zyla Life Sciences, Inc.2$26
Currax Pharmaceuticals LLC2$25
Axsome Therapeutics, Inc.1$25
Avion Pharmaceuticals1$18
Corium, LLC1$15
Neuropace, Inc.1$15
Adamas Pharmaceuticals, Inc.1$14
Octapharma USA, Inc.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Impel Pharmaceuticals Inc.1$13
Banner Life Sciences, LLC1$13
Mallinckrodt Enterprises LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,333 in reported general payments places this provider in the 65th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$142,261
Medicare patients
515
Services billed
2,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5044$653,286
IngrezzaValbenazine Tosylate38$313,762
Nurtec OdtRimegepant Sulfate45$65,949
QuliptaAtogepant42$59,048
Aimovig AutoinjectorErenumab-Aooe47$34,088
BriviactBrivaracetam17$28,829
VimpatLacosamide30$26,959
Oxtellar XrOxcarbazepine12$24,128
Lacosamide96$22,192
OnfiClobazam12$20,883
XcopriCenobamate13$17,771
Emgality PenGalcanezumab-Gnlm18$17,203
Pregabalin189$11,978
LamictalLamotrigine12$10,851
Oxcarbazepine156$10,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$267$313,76238 claims
PfizerNurtec Odt, Dilantin$712$73,15070 claims
AbbVieQulipta$759$59,04842 claims
UCB, Inc.Briviact, Vimpat$596$55,78847 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$202$24,12812 claims
Lundbeck LLCOnfi$124$20,88312 claims
SK Life Science, Inc.Xcopri$120$17,77113 claims
Upsher-smith Laboratories LLCTopiramate$76$5,495249 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$271$1,50012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 neurology providers in Indiana.

Other neurology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →